DLA Piper advises Mérieux Equity Partners on the acquisition of a majority stake in curea medical

DLA Piper has advised healthcare-focused European investment firm Mérieux Equity Partners on the acquisition of a majority stake in curea medical, a carve-out from McAirlaid's. The investment aims to support curea’s growth and innovation in advanced wound care solutions while expanding its international reach.

Mérieux is acquiring its majority stake in curea medical through a primary LBO. As part of the transaction, McAirlaid’s will reinvest a portion of its proceeds. The management team, including CEO Andreas Bolz will also invest alongside McAirlaid’s and MxEP. The acquisition was made through Mérieux’ Participations 4 Fund (MP4) marking its tenth transaction and its first investment in Germany.

Curea medical, founded in 2010, is a Germany-based manufacturer of specialised solutions for wound care. The company has established itself as a major player in the field of advanced wound dressings, supplying home care services, hospitals and pharmacies across Europe, particularly in Germany.

Founded in 2009, Mérieux Equity Partners is an investment manager specialising in healthcare and nutrition through two platforms: Venture and Growth/Buyout. Mérieux currently manages funds with a total volume of more than EUR1.5 billion.

The DLA Piper team was led by partner Lars Jessen (Private Equity/M&A) and senior associate Daniel Osmanovic (Corporate/M&A; both Frankfurt), with counsel Till Burmeister (Private Equity/M&A, Hamburg), Sven Bischoff (Tax), and associate Felix Groppenbächer (Corporate/M&A; both Frankfurt) in the core team.

Partner Dr Wolfram Distler, counsel Patrick Reuter and associate Sindy Martin (all Finance, Frankfurt) advised on the acquisition financing for the purchase of curea medical.

The team also included partners Dr med Kokularajah Paheenthararajah (Life Sciences/Patent Litigation, Cologne), Dr Nico Brunotte (IT), Dr Henriette Norda (Employment), Verena Grentzenberg (Data Protection; all Hamburg), Dr Konrad Rohde (Tax), Semin O (Antitrust; both Frankfurt), Dr Moritz von Hesberg (Corporate/M&A, Hamburg) and Dr Thilo von Bodungen (Commercial, Munich); counsel Dr Enno Ahlenstiel (Antitrust), Dr Thilo Streit (Public Law; both Cologne), and Thomas Gericke (Tax, Frankfurt); senior associates Hannah Modi (Employment, Hamburg), Hauke Tammert (Public Law, Cologne), Andreas Rüdiger (Cologne), David Schele (Hamburg; both Data Protection), Dr Betina Fischer (Hamburg), and Gerald Baumgartner (Munich; both Commercial); associates Lara Joy Pabst (Private Equity/M&A, Frankfurt), Philipp Schmechel (Hamburg), Dr Philipp Adelberg (Cologne; both Data Protection), Jule Lange (Employment, Hamburg), Pia Riemenschneider, Mikael Kurki, Dr Carl Prior (all Life Sciences/Patent Litigation, Cologne), Romano Nicklas (Commercial, Munich), Jannik Becker (Tax, Frankfurt) and Melanie Bierwirth (Corporate/M&A, Hamburg).

Additionally, a team from the Paris office advised on French legal and tax aspects, including partners Sarmad Haidar (Private Equity/M&A), Fanny Combourieu, and Raphaël Béra (both Tax); counsel Louis-Augustin Jourdan and Thomas Guillier (both Tax); associates Florian de Vienne (Tax) and Loïc Bustos (M&A); and legal director Cécile Szymanski (Corporate).